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Introduction: We investigated tolerable doses to organs at risk 
(OARs) in the mediastinum and pulmonary hilum following stereo-
tactic body radiotherapy for centrally located lung tumors.
Methods: Between 2005 and 2012, 381 patients with lung tumors 
were treated with stereotactic body radiotherapy of 40 to 60 Gy in 
five fractions. From among these patients, we extracted those who 
received greater than 25 Gy irradiation to OARs and analyzed dosi-
metric factors in relation to grade 3 to 5 toxicities.
Results: In total, 398 OARs in 133 patients were analyzed, with 
a median follow-up of 33 (range, 3–87) months. The numbers 
receiving greater than 25 Gy irradiation to the aorta, vena cava, 
pulmonary artery, pulmonary vein, bronchus, trachea, heart, and 
esophagus were 72, 33, 73, 60, 55, 13, 69, and 23, respectively. The 
corresponding median Dmax 0.5 ml were 43.8, 32.0, 32.2, 29.1, 
28.4, 28.7, 41.1, and 21.7 Gy. Of these patients, two developed 
grade 5 and one grade 3 hemoptysis, and two had grade 3 obstruc-
tive pneumonia. Two patients with grade 5 hemoptysis received 
high doses at the pulmonary artery and bronchus (59.2 and 54.4 
Gy, and 61.3 and 59.6 Gy, respectively). No other grade 3 to 5 tox-
icities occurred.
Conclusion: Therapeutic indications and dose-intensity should be 
carefully determined for patients with central tumors, especially 
when doses to the pulmonary artery and bronchus in the pulmonary 
hilum exceed 50 Gy. Tolerable doses for other OARs might, however, 
be higher than in this study, though longer follow-up is necessary to 
assess this possibility.
Key Words: Toxicities, Stereotactic body radiotherapy, Organs at 
risk, Centrally located lung tumor, Dose–volume histograms.
(J Thorac Oncol. 2014;9: 1370–1376)
Stereotactic body radiotherapy (SBRT) is a promising new technology for the treatment of peripheral non–small-cell 
carcinoma, showing excellent therapeutic efficacy with only 
mild toxicities.1 In retrospective analyses, the cancer-specific 
survivals following SBRT were equivalent to those following 
surgery.2,3 However, for patients with centrally located lung 
tumors, a high-dose regimen is difficult to apply due to exces-
sive toxicity.4,5 In a prospective phase II trial of SBRT with 
doses of 60 to 66 Gy in three fractions, grade 3 to 5 toxicities 
occurred in six of 22 patients (27.3%) with central tumors.6 
In an attempt to decrease the risk of serious toxicities from 
SBRT for central tumors, more protracted regimens have been 
used.7–9
Even though dose constraints for normal tissues have 
been reasonably validated for conventionally fractionated 
radiotherapy, there have been a few reports of dose constraint 
analysis of SBRT for central tumors.10
Since 2005, we have cautiously treated patients with 
tumors adjacent to the mediastinum and/or the hilum, apply-
ing modestly reduced doses. The aim of this study is to retro-
spectively investigate tolerable doses to organs at risk (OARs), 
including the aorta, vena cava, pulmonary artery, pulmonary 
vein, bronchus, trachea, heart, and esophagus, in a large series 
of patients undergoing SBRT for central tumors.
PATIENTS AND METHODS
Patients
Between 2005 and 2012, 381 patients with solitary 
lung tumors, but neither regional nor distant metastasis, 
were treated with SBRT. These patients had tumors that 
were regarded as inoperable or high-risk operable, or had 
refused surgery. For this analysis, we extracted patients who 
satisﬁed the following criteria: central tumors which were 
deﬁned as the area within 2 cm of the proximal bronchial 
tree,4 or within 2 cm of the mediastinum; at least one OAR, 
involving the aorta, superior or inferior vena cava, pulmo-
nary artery, pulmonary vein, bronchus, trachea, heart, and/
or esophagus, was irradiated with greater than 25 Gy. These 
patients were followed up for at least 12 months or until 
death (Fig. 1).
Informed consent was obtained from all the partici-
pating patients. The Ofuna Chuo Hospital Review Board 
approved this study.
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Stereotactic Body Radiotherapy
Our SBRT techniques have already been described in 
detail.11,12 In brief, after immobilizing the patient with a vac-
uum pillow, abdominal pressure corsets are used, if necessary, 
to assure that the tumor motion is maintained below 1 cm. For 
the treatment-planning computed tomography (CT) scans, we 
use the long-scan-time CT technique11 to directly visualize 
the internal target volume. The planning target volume (PTV) 
is defined by adding 6 to 8 mm margins to the internal target 
volume in all the directions. Dynamic conformal multiple arc 
therapy and image matching with cone beam CT or CT in 
room were used in most of the cases.12
Until 2006, SBRT for central tumors was performed 
with the dose of 50 Gy in five fractions on consecutive days 
prescribed to the 80% isodose line covering the PTV. Between 
2006 and 2011, the dose was modified to 40 Gy. From 2011 
onward, the dose was raised to 50 Gy when PTVs did not 
include the OARs and 40 Gy when they did, with all irradia-
tions being prescribed to the 60% isodose line.13
In treatment planning, we attempted to keep the doses 
delivered to the esophagus and trachea within 25 Gy, and to 
minimize the doses for the bronchus, pulmonary artery, and 
left ventricle as low as reasonably achievable. No dose con-
straints were applied to the aorta or the vena cava.
Delineation and Dose Quantiﬁcation of OARs
For OAR delineation, the bronchus consisted of the bilat-
eral mainstem bronchi, upper lobe bronchi, the intermedius 
bronchus, the right middle lobe bronchus, the lingular bronchus, 
and the bilateral inferior lobe bronchi.14 The heart was contoured 
along with the pericardial sac, and the superior aspect (or base) 
began at the level of the inferior aspect of the aortic arch (aorto-
pulmonary window) and extended inferiorly to the apex of the 
heart.15 The pulmonary artery was contoured to include the pul-
monary trunk, bilateral pulmonary arteries, bilateral superior 
lobar arteries, middle lobar artery, lingular artery, and bilateral 
inferior lobar arteries. The pulmonary vein was contoured to 
include the bilateral superior and inferior pulmonary veins.
According to the criteria established by the University 
of Texas Southwestern Medical Center (UTSWMC),16 the 
maximum point dose constraints for the OARs in the mediasti-
nal and hilar regions were all 35 Gy or greater in five fractions. 
To be on the safer side, we extracted patients in whom irra-
diation to the OARs exceeded 25 Gy. In addition, these OARs 
were delineated in the area irradiated with greater than 15 Gy.
The OARs were evaluated using dose–volume histo-
grams (DVHs). For the OAR evaluations, the maximum doses, 
minimum doses delivered to 0.5 ml of the most irradiated 
OAR volumes (Dmax 0.5 ml) and Dmax 1 ml, and the absolute 
volumes receiving greater than 25 Gy (V25) and greater than 
50 Gy (V50) of each organ were recorded.
Follow-Up and Toxicity Assessment
Our follow-up procedures were previously described in 
detail.17 In brief, all patients were followed up monthly during 
the first 6 months. Follow-up CT scans were performed at 1 
and 3 months after SBRT and thereafter at 3-month intervals 
during the first 2 years. Subsequently, follow-up interviews 
and CT scans were obtained at 4- to 6-month intervals. One 
year after SBRT, [18F]-ﬂuorodeoxyglucose positron emission 
tomography/CT and brain magnetic resonance imaging were 
performed.
Grade 3 to 5 toxicities of each OAR were scored accord-
ing to the Common Terminology Criteria for Adverse Events, 
version 4.
The UTSWMC published their SBRT dose constraints.16 
Dosimetric parameters of OARs in our study were compared 
with their dose constraints.
RESULTS
Among 381 patients undergoing SBRT, 133 met the 
criteria for this study (Fig. 1). The patient characteristics are 
shown in Table 1. The median follow-up was 33 (range, 3–87) 
months. Fifteen patients were clinically diagnosed as hav-
ing T4 tumors, based on the invasion of major vessels, the 
mediastinum, and the heart in nine, five, and one, respectively. 
The 3-year local control, overall survival, and cancer specific 
survival rates were 78.0%, 54.1%, and 68.3%, respectively. 
The numbers of patients whose tumors were irradiated with 
FIgURE 1.  Flow chart of the patients in this study. 
SBRT, stereotactic body radiotherapy; OARs, organs 
at risk.
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greater than 25 Gy to the aorta, vena cava, pulmonary artery, 
pulmonary vein, bronchus, trachea, heart, and esophagus were 
72, 33, 73, 60, 55, 13, 69, and 23, respectively. Typical tumor 
locations of these OARs are shown in Figure 2.
Figure 3 shows the DVH for each OAR. There were 
two patients with grade 5 hemoptysis which occurred 13 and 
16 months after SBRT, one with grade 3 hemoptysis which 
occured 19 months after SBRT, and two with grade 3 obstruc-
tive pneumonia which occured 27 and 32 months after SBRT.
In the two patients with grade 5 hemoptysis, the primary 
tumors were completely controlled on [18F]-ﬂuorodeoxyglucose 
positron emission tomography/CT performed at 2 and 4 months, 
respectively, before death. Figure 4 shows pretreatment and fol-
low-up images from one of these patients. The other patient had 
an intrapulmonary metastasis 12 months after the first SBRT 
and was treated with second SBRT at 1 month before death. 
For this patient, Dmax 0.5 ml with the second SBRT to the pul-
monary artery and the bronchus were 8.3 and 10.1 Gy in five 
fractions, respectively. The patient with grade 3 hemoptysis had 
Churg–Strauss syndrome as comorbidity and had thus been 
receiving steroid therapy. Transcatheter arterial embolization of 
the pulmonary artery branch was performed as a rescue treat-
ment. In the two patients with grade 3 obstructive pneumonia, 
bronchial strictures without tumor recurrences were observed 
employing bronchoscopy. Both patients suffered multiple epi-
sodes of pneumonia, and were treated with antibiotics.
There were no grade 3 to 5 adverse events involving the 
aorta, vena cava, pulmonary vein, trachea, heart, or esophagus.
The dosimetric parameters are shown in Table 2. For 
the pulmonary artery and bronchus in the two patients with 
grade 5 hemoptysis, Dmax, Dmax 0.5 ml, and Dmax 1.0 ml 
all exceeded 50 Gy. The tumors were located at the pulmo-
nary hilum in both the patients. In contrast, the tumors of the 
patients who did not experience grade 3 to 5 toxicities despite 
high-dose irradiation of the pulmonary artery were located 
near the pulmonary trunk (Fig. 2C).
The maximum point dose constraints in five fractions 
suggested by the UTSWMC delivered to the great vessels, tra-
chea and large bronchus, heart, and esophagus were 53, 40, 
38, and 35 Gy, respectively.16 In this study, there were 134 
OAR sites, in 65 patients, exceeding their dose constraints. 
Of these patients receiving doses exceeding the constraints 
for the pulmonary artery (n = 14) and the bronchus (n = 27), 
there were two (14%) with grade 5 and one (7%) with grade 
3 hemoptysis related to the pulmonary artery and two (7%) 
with grade 5 hemoptysis and two (7%) with grade 3 obstruc-
tive pneumonia related to the bronchus. However, none of the 
patients receiving point doses to the aorta (n = 20), vena cava 
(n = 6), pulmonary vein (n = 10), trachea (n = 4), heart (n = 
50), or esophagus (n = 3), exceeding the maximum recom-
mended, developed grade 3 to 5 toxicities.
TABLE 1.  Patients and Tumors Characteristics
No. of patients 133
Median age (range), years 78 (57–91)
Sex: male/female 91/42
Median follow-up duration (months) 33 (3–87)
Median GTV (ml) 12.8 (0.8–77.2)
Median PTV (ml) 40.5 (11.5–169.5)
Median maximum diameter of tumor (cm) 3.0 (1.0–6.2)
Histology
  Pathology-proven NSCLC 66
  Pathology unproven 53
  Metastasis 14
T stage: T1/T2/T3/T4 66/36/2/15
Prescribed dose: 40 Gy/50 Gy/60 Gy 51/80/2
No. of tumors: adjacent to
  Aorta 72
  Vena cava 33
  Pulmonary artery 73
  Pulmonary vein 60
  Heart 69
  Esophagus 23
  Trachea 13
  Bronchus 55
GTV = gross tumor volume; PTV = planning target volume; NSCLC = non–small-
cell lung cancer.
FIgURE 2.  Typical computed tomography images 
of tumors adjacent to or invading the organs at risk 
in the central region. A, Aorta, (B) vena cava, (C) 
pulmonary artery (without bronchus), (D) pulmo-
nary vein, (E) heart, (F) trachea and esophagus.
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DISCUSSION
Several reports have focused on severe toxicities after 
SBRT for central tumors,4–6 and alternative dose fractionation 
schedules have been applied in the efforts to reduce these tox-
icities.7–9 In our institution, patients with central tumors have 
generally been treated with lower fractionated doses than those 
harboring peripheral tumors without changing the number of 
fractions. Herein, we retrospectively investigated tolerable 
doses to OARs located in the mediastinum and the hilum. To 
our knowledge, this is the first study on integrated dosimetric 
analysis of irradiation doses to OARs in the patients undergo-
ing SBRT for central tumors.
The UTSWMC dose constraints serve as a useful ref-
erence of SBRT for central lung tumors. However, as noted 
FIgURE 3.  Dose–volume histograms of the organs at risk in the central region. A, aorta, (B) bronchus, (C) esophagus, (D) 
heart, (E) pulmonary artery, (F) pulmonary vein, (G) trachea, (H) vena cava. The bold black lines represent three cases with 
hemoptysis, the dotted-lines represent two cases with obstructive pneumonia.
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in that publication, SBRT dose constraints have not yet been 
validated with solid long-term data. Thus, the UTSWMC 
guidelines were presented as recommendations rather than 
requirements. We found the constraints suggested by the 
UTSWMC to be applicable to some OARs and not to the 
others. None of the patients satisfying the UTSWMC dose 
constraints experienced grade 3 to 5 toxicities. None of the 
patients receiving point doses to the aorta, vena cava, pulmo-
nary vein, exceeding the constraints, developed grade 3 to 5 
toxicities. Meanwhile, some of the patients who had received 
doses exceeding the constraints for the pulmonary artery and 
the bronchus experienced grade 3 to 5 toxicities. According to 
these results, the dose constraints to great vessels appear to be 
applicable to the pulmonary artery, while the aorta, vena cava, 
and pulmonary vein may show greater tolerance at higher 
doses. In addition, the pulmonary artery is known to be thin-
walled and easily injured intraoperatively, as compared with 
the other great vessels.18 The establishment of separate dose 
constraints for each great vessel would likely be beneficial.
Two patients with grade 5 hemoptysis died due to sud-
den onset of massive hemoptysis more than a year after SBRT. 
Both the patients received high-dose irradiation to the pulmo-
nary artery and bronchus near the pulmonary hilum, which 
run parallel to each other (Fig. 4). In contrast, there were no 
severe toxicities in patients who received high-dose irradia-
tion only to the pulmonary trunk, located in the mediasti-
num (Fig. 2C). One of the patients with grade 5 hemoptysis 
received second SBRT for intrapulmonary metastasis dur-
ing the follow-up period. In this patient, a possibility of the 
second SBRT-related toxicity could not be completely ruled 
FIgURE 4.  A patient with grade 5 hemoptysis 
after SBRT. A, Enhanced CT and (B) 18F-FDG PET/
CT before SBRT suggest tumor invasion to the right 
pulmonary artery and right main bronchus. C, D, 
Planning CT with dose distribution curves of SBRT 
(axial and coronal images). A prescribed dose of 
50 Gy was delivered in five fractions, with isodose 
lines from the outer to the inner representing 12.5, 
25, 37.5, 50, and 56.3 Gy, respectively. E, Plain CT 
16 months after SBRT and (F) 18F-FDG PET/CT 13 
months after SBRT shows a complete response for 
the primary tumor. SBRT, stereotactic body radiation 
therapy; CT, computed tomography; 18F-FDG PET, 
[18F]-fluorodeoxyglucose positron emission.
TABLE 2.   Dosimetric Characteristics of Organs at Risk
Dmax (Gy) Dmax 0.5 ml (Gy) Dmax 1.0 ml (Gy) V25 (ml) V50 (ml) (n)
Median (Range) Median (Range) Median (Range) Median (Range) Median (Range)
Aorta (n = 72) 44.7 (25.9–77.8) 43.8 (19.9–66.0) 42.5 (18.2–60.6) 9.90 (0.01–53.10) 2.48 (0.01–8.31) (n = 24)
Vena cava (n = 33) 41.0 (25.9–60.7) 32.0 (21.6–54.1) 28.0 (18.1–52.1) 1.26 (0.02–14.01) 0.50 (0.01–1.54) (n = 8)
Pulmonary artery (n = 73)
  No toxicity (n = 70) 42.2 (25.5–64.2) 30.6 (16.5–60.1) 25.6 (12.3–56.0) 1.35 (0.01–17.62) 0.42 (0.01–1.79) (n = 13)
  Hemoptysis grade 5 (n = 2) 60.2, 62.4 59.2, 61.3 58.4, 60.5 5.32, 9.79 3.58, 3.77
  Hemoptysis grade 3 (n = 1) 53.2 39.5 30.3 1.34 0.05
Pulmonary vein (n = 60) 41.5 (26.4–63.3) 29.1 (15.8–53.8) 23.4 (12.2–43.7) 0.80 (0.01–3.76) 0.07 (0.01–0.62) (n = 13)
Bronchus (n = 55)
  No toxicity (n = 50) 39.4 (26.1–62.2) 27.4 (16.4–59.2) 23.2 (12.9–50.4) 0.83 (0.01–7.09) 0.13 (0.01–1.04) (n = 8)
  Hemoptysis grade 5 (n = 2) 58.0, 61.4 54.4, 59.6 52.0. 58.5 3.97, 6.41 1.37, 2.45
  Hemoptysis grade 3 (n = 1) 39.2 24.9 21.8 0.49 NA
  Obstructive pneumonia (n = 2) 49.2, 49.8 41.5, 47.7 36.3, 46.3 2.37, 3.99 NA
Trachea (n = 13) 33.3 (25.3–58.8) 28.7 (19.7–49.8) 26.4 (17.9–45.4) 1.46 (0.01–7.94) 0.476 (n = 1)
Heart (n = 69) 45.3 (25.9–72.8) 41.1 (22.7–65.8) 37.8 (19.4–62.1) 8.48 (0.05–59.16) 0.94 (0.01–7.55) (n = 2)
Esophagus (n = 23) 28.4 (25.6–40.8) 21.7 (15.7–32.0) 19.5 (13.3–29.9) 0.06 (0.01–3.16) NA
Dmax = maximum dose; DXml = minimum doses delivered to X ml of the most irradiated OAR volumes; VX = absolute volumes receiving >X Gy; NA = not available; OAR, 
organs at risk.
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out. However, he had intermittent bloody sputum before the 
second SBRT. In addition, prominent fibrotic change was 
seen in the interstitium around the pulmonary artery and the 
bronchus before the second SBRT, and the dose to the pul-
monary hilum in the second SBRT was low. Therefore, the 
first SBRT was thought to have a profound effect on bleeding 
in this patient, and DVH was analyzed for the first treatment. 
These results indicate that a high-dose irradiation to the pul-
monary hilum may be especially critical as Timmerman et al. 
reported,4 though we could not confirm whether the source of 
bleeding was the pulmonary artery or a bronchial artery in 
the two patients. One patient with grade 3 pulmonary artery 
bleeding also received SBRT to the region of the pulmonary 
hilum, with a moderate dose being delivered to the pulmonary 
artery and bronchus. However, she had the comorbidity of 
Churg–Strauss syndrome which is characterized by vasculitis 
and often causes alveolar hemorrhage.19 Therefore, SBRT was 
unlikely to have been the sole cause of bleeding in this case.
Along with the maximum point dose constraints, those 
applied to certain small volumes have also been investigated 
for serial organs. The UTSWMC provided dose constraints 
defined by various volumes (e.g., 47 Gy for Dmax 10 ml of 
the great vessels, or 21 Gy for Dmax 0.5 ml of the bronchus-
smaller airways).16 However, these parameters are not readily 
applicable in clinical settings because the volumes are rather 
large for typical SBRT dose distributions given the tight con-
formity with a steep dose fall-off. In a phase Ⅲ randomized 
trial of either surgery or stereotactic radiotherapy for early 
stage (IA) lung cancer (ROSEL study), the dose constraints 
were defined based on 1 ml (except for the spinal cord), to 
prevent excessive dependency on the calculation grid size in 
the evaluation of these parameters.20 In a report from the MD 
Anderson Cancer Center, which investigated the dose limits 
for the aorta after re-irradiation of lung tumors, aortic dose 
constraints were evaluated using the maximum cumulative 
dose to 1 ml of the aorta.21 In a retrospective study, radiation-
induced atelectasis was evaluated according to the dose deliv-
ered to 0.1 to 2.0 ml of the bronchus.10 On the basis of these 
reports, we assessed Dmax, Dmax 0.5 ml, and Dmax 1.0 ml 
in this study and considered Dmax 0.5 ml as one of the valid 
parameters for serial OARs (Table 2).
The treatment of central tumors represents a high-risk 
clinical situation for any therapeutic modality. Although 
patients who receive sleeve pneumonectomy may generally 
be in good medical condition, the postoperative severe com-
plication and 30-day mortality rates are reportedly 3% and 
25%, respectively.22 With conventional radiotherapy using a 
relatively high total dose (86 Gy in 43 fractions), which is 
estimated to be a lower effective dose biologically than those 
employed in most SBRT schedules, there was a 25% risk of 
bronchial stenosis.23 Song et al.5 reported that three of the nine 
patients who received SBRT for central tumors experienced 
grade 3 to 5 toxicities, while Haasbeek et al.9 found risk-adap-
tive SBRT to be tolerable for patients with central tumors.
Although dose reduction would decrease severe toxici-
ties, it would also result in an increased rate of local tumor-
control failure. In fact, a high-dose regimen of 54 Gy in three 
fractions achieved good outcomes, with a 3-year local control 
rate being 97.5%.1 On the other hand, poorer outcomes have 
been reported with relatively low-dose regimens for central 
tumors, with a 3-year local control rates of 29 to 72%.24–26 
In addition, statistically significant correlations between the 
doses and local control rates or overall survival have been 
reported.27,28 Therefore, the risks and benefits should be fully 
discussed with the patients before obtaining informed consent, 
because it is often the case that no other treatment options are 
available. In our institution, patients with central tumors have 
been actively and meticulously treated, achieving a 3-year 
local control and overall survival rates of 78.0% and 54.1%, 
though two of our 133 patients experienced grade 5 toxicities. 
Establishing optimal SBRT doses for central tumors and dose 
constraints applicable to OARs requires dosimetric analyses 
of data from large cohorts.
This study has limitations. First, the analysis is based 
on a small number of events, which limits our ability to sta-
tistically assess and generalize our findings. Given the paucity 
of clinical information on this topic, however, we believe that 
our findings provide useful information for patients and physi-
cians contemplating SBRT for central tumors. Another limita-
tion is the short median follow-up period of only 33 months. 
Longer follow-up may reveal additional toxicities. Finally, this 
was a retrospective study. Currently, a phase I/II study is being 
conducted by the radiation therapy oncology group (RTOG-
0813). The doses and volume constraints used herein were 
thus based on those provided by the UTSWMC. The results 
of the RTOG-0813 study are expected to add new information 
on the safety of SBRT for central tumors treated within RTOG 
dose constraints.
In conclusion, most patients with central tumors in this 
study tolerated SBRT with a low incidence of grade 3 to 5 
toxicities, despite the delivery of high doses of irradiation to 
OARs in the mediastinum. However, our results indicate that 
attention is needed regarding the pulmonary artery and the 
bronchus, particularly in the pulmonary hilum, when doses 
exceed 50 Gy in five fractions. It is important to maintain a 
good balance between therapeutic efficacy and toxicity. Large-
scale prospective studies with long follow-up providing more 
information on tolerable doses for OARs are needed to achieve 
greater efficacy and safety of SBRT for central tumors.
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